S
Sara I. Ramos
Researcher at University of Extremadura
Publications - 9
Citations - 886
Sara I. Ramos is an academic researcher from University of Extremadura. The author has contributed to research in topics: Debrisoquine & Fluvoxamine. The author has an hindex of 9, co-authored 9 publications receiving 858 citations. Previous affiliations of Sara I. Ramos include Karolinska Institutet.
Papers
More filters
Journal ArticleDOI
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
Leif Bertilsson,Juan Antonio Carrillo,Marja-Liisa Dahl,Adrián LLerena,Christina Alm,U Bondesson,L Lindstrom,I Rodriguez de la Rubia,Sara I. Ramos,Julio Benítez +9 more
TL;DR: This study suggests that clozapine is metabolised by CYP1A2 to a major extent and no significant relationships with xanthine oxidase and N-acetyl transferase activity, also assessed by a caffeine test, were found.
Journal ArticleDOI
Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
Juan Antonio Carrillo,Angustias G. Herraiz,Sara I. Ramos,Guillermo Gervasini,Sonia Vizcaino,Julio Benítez +5 more
TL;DR: Smoking-induced increased CYP1A2 activity significantly diminished plasma olanzapine concentrations and the antipsychotic effect of the drug, and such inhibition can contribute to adverse drug interactions.
Journal ArticleDOI
Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.
Juan Antonio Carrillo,Magnus Christensen,Sara I. Ramos,Christina Alm,Marja-Liisa Dahl,Julio Benítez,Leif Bertilsson +6 more
TL;DR: Among caffeine-based approaches for CYP1A2, the authors recommend either plasma or saliva 17X/ 137X ratio and the urinary (AFMU + 1U + 1X + 17U + 17X)/137X ratio during a sampling interval of at least 8 hours, starting at time zero since caffeine intake.
Journal ArticleDOI
Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
Magnus Christensen,Magnus Christensen,Gunnel Tybring,Gunnel Tybring,Kazuo Mihara,Kazuo Mihara,Norio Yasui‐Furokori,Norio Yasui‐Furokori,Juan Antonio Carrillo,Juan Antonio Carrillo,Sara I. Ramos,Sara I. Ramos,Katarina Andersson,Katarina Andersson,Marja-Liisa Dahl,Marja-Liisa Dahl,Leif Bertilsson,Leif Bertilsson +17 more
TL;DR: Whether nontherapeutic doses of fluvoxamine inhibit CYP1A2 but possibly not CYP2C19 is investigated.
Journal ArticleDOI
Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients.
TL;DR: Changes in the habitual caffeine intake alter the metabolism of CLZ in schizophrenic patients, and patient intake of caffeine should be medically supervised, and the monitoring of Clozapine and metabolite levels may be warranted.